Thai Government-Government House News-“Coronavirus” reveals progress in research, development, and production of vaccines to prevent coronavirus disease 2019 (COVID-19) in Thailand.

Thai Government-Government House News-“Coronavirus” reveals progress in research, development, and production of vaccines to prevent coronavirus disease 2019 (COVID-19) in Thailand.
Thai Government-Government House News-“Coronavirus” reveals progress in research, development, and production of vaccines to prevent coronavirus disease 2019 (COVID-19) in Thailand.
--

27/12/2023

print

Today (27 Dec. 2023) Mrs. Radklao Inthawong Suwankiri, Deputy Spokesperson for the Office of the Prime Minister, revealed that the Cabinet has acknowledged the National Vaccine Committee (NRCT)’s proposal of progress in the research, development, and production of disease prevention vaccines. Infected with coronavirus 2019 (COVID-19) in Thailand by the COVID-19 vaccine researched and developed by the Government Pharmaceutical Organization. The trade name HXP – GPOVAC has received conditional registration approval (Conditional Approval) from the Food and Drug Administration (FDA) on September 28, 2023.

Mrs. Radklao said that from the situation of the COVID-19 outbreak that began to spread into Thailand since the beginning of January 2020, NSTDA, Ministry of Public Health The National Vaccine Institute (NST) has created a Blueprint plan for Thai people’s access to COVID-19 vaccines. It is used as a policy framework for integrating and coordinating cooperation between agencies in all sectors, both the public and private sectors. This is in line with the National Vaccine Security Policy and Strategic Plan 2020-2022 and received approval from the NSTDA on April 22, 2020. The NSTDA has been operating under the Blueprint plan since. Year 2020 can be summarized as follows:

1. Development of prototype vaccines in Thailand from upstream Potential agencies in the country have carried out research and development of COVID-19 vaccines under various technology platforms, with success and progress. It can be summarized as follows: (1) Inactivated recombinant viral vectorvaccine Researched by the Government Pharmaceutical Organization which received conditional registration (Conditional Approval) on September 28, 2023 using the trade name HXP-GPOVAC and is used in the target group for people aged 18 years and over. (2) The mRNA vaccine has been Research by the Vaccine Research Center of Chulalongkorn University. Faculty of Medicine Chulalongkorn University is currently waiting for approval from the FDA to conduct a phase 2 human research study. (3) Protein subunit (Plant-based) vaccine has been researched by Baiya Phytopharm Company Limited, which has received permission. Produce drug samples to request registration of a drug formula according to Form Por.Yor.8 on October 4, 2023. Currently, preparations are underway to test the vaccine on humans, and (4) DNA vaccines have been researched by the company. Bionet-Asia Co., Ltd., despite not being able to complete the phase 1 study in humans, will be able to utilize the potential of its vaccine manufacturing facility to support the production of Nucleic acid3 vaccine.

2. Collaborating with foreign countries to receive transfer of vaccine production technology, with the FDA evaluating and considering information on the quality of the AstraZeneca vaccine. produced by the company Siam Bioscience Co., Ltd. was found to be comparable to the quality of the registered vaccine produced in Italy. Therefore, the FDA approved the addition of the company. Siam Bioscience Co., Ltd. is the production site for AstraZeneca’s COVID-19 vaccine on April 23, 2021, and at the end of fiscal year 2021, Siam Bioscience Co., Ltd. was able to deliver the vaccine. Complete amount of 61 million doses

and 3. Purchasing and procuring vaccines by booking in advance from the company. 26 million doses of AstraZeneca, which the contract was signed on November 27, 2020, and there are negotiations to purchase an additional 35 million doses of the vaccine, amending the original contract. This eliminates the need to pay additional vaccine reservation fees. Including the procurement of vaccines from the company. A total of 61 million doses of AstraZeneca will be administered to Thai people in 2021-2022.

The article is in Thai

Thailand

Tags: Thai GovernmentGovernment House NewsCoronavirus reveals progress research development production vaccines prevent coronavirus disease COVID19 Thailand

-

NEXT ‘Somsak’ reveals he really doesn’t know ‘Cabinet reshuffle’ sits ‘Minister of Public Health’ points out ‘Anucha’ is fine.